TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03541070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Description: Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
Study: NCT00765388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Uro
Description: The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hollister
Description: The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
Study: NCT01245712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Undergo APBI delivered with proton radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo APBI delivered with proton radiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00584727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens
Study: NCT00149513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Case Management
Description: A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care.
Study: NCT01064232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone Tablets 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone Tablets 1 mg
Study: NCT02464449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: AI-CBT
Description: AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Standard Telephone CBT
Description: Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
Study: NCT01177904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cease progsterone at 5
Description: Cease administration of progsterone at first US at 5 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: control group: progesterone 8
Description: Control group: progesterone until 8 weeks of pregnancy
Study: NCT00419263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 150 mg
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 300 mg
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
Study: NCT02567084

Intervention type: DEVICE
Group type: OTHER
Intervention: CERAMENT™ |BONE VOID FILLER
Description: Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
Study: NCT05045625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Study Electrode
Description: The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
Study: NCT02990533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Study: NCT02880475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXN PR tablet
Description: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXN PR tablet
Description: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
Study: NCT02990533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Study: NCT03015402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: 40 mg PO (by mouth) TID (three times each day) for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
Study: NCT00528775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: 4 mg/m2 IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic procedure
Description: Treatment with 150 joules from laser
Study: NCT00712361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)
Description: Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
Study: NCT00775710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal non-invasive ventilation
Description: Prolongation of non-invasive ventilation during 3 nights.
Study: NCT02451527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
Study: NCT04181528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty implant
Description: In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty implant
Description: In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
Study: NCT03773250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: The intervention has an intensive phase and a maintenance phase.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral intervention
Description: The intervention has an intensive phase and a maintenance phase.
Study: NCT04724538

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-pertechnetate aerosol
Description: 99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-pertechnetate aerosol
Description: 99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
Study: NCT02451527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
Study: NCT03407599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart
Description: An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
Study: NCT00781729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga, one hour class, 3 times per week, for 24 weeks
Description: Yoga, one hour class, 3 times per week, for 24 weeks
Study: NCT03407599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart
Description: An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart (NovoRapid®)
Description: An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart (NovoRapid®)
Description: An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
Study: NCT02955264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-Galactose
Description: D-Galactose is an oral powdered dietary supplement to be taken by mouth.
Study: NCT05502432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation
Description: Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
Study: NCT00781729

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Luncheon Seminar Series, once per month, for 24 weeks
Description: Luncheon Seminar Series, once per month, for 24 weeks
Study: NCT02882360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerlix-AMD
Description: Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerlix-AMD
Description: Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo--normal gauze
Description: Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo--normal gauze
Description: Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
Study: NCT03655769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
Study: NCT02060851

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard PN
Description: Group 1: a control group who received standard PN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vifor
Description: iron sucrose, 200 μg/kg per day, was given everyday with PN,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vifor and EPO
Description: EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
Study: NCT03792126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Learning Approach
Description: All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA.
Study: NCT03419481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg every 3 weeks infusion
Study: NCT04016090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid (5 mg)
Study: NCT01355575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
Study: NCT03455101

Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.
Study: NCT04159454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PITA
Description: Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate \~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
Study: NCT02507141

Intervention type: DEVICE
Intervention: Reflectance Confocal Microscopy
Description: Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
Study: NCT04850352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heukcha Extracts
Description: Experimental group: Heukcha Extracts

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study: NCT04589936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone positioning
Description: Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
Study: NCT04016090

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT01781728

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
Study: NCT03860168

Intervention type: OTHER
Group type: OTHER
Intervention: PICU Up!
Description: The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
Study: NCT01527929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study: NCT01022762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Individually adjusted dose for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gliclazide
Description: Individually adjusted dose for 16 weeks
Study: NCT03595917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Description: •ABL001 is administered daily per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Fixed doses oral once a day per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
Study: NCT03215797

Intervention type: DRUG
Group type: OTHER
Intervention: phenylephrine
Description: phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
Study: NCT02411565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Wheat Germ Extract (FWGE)
Description: 5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: Planned Surgery
Description: Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care: Planned Surgery
Description: Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life (QoL) Surveys: FACT-O
Description: Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life (QoL) Surveys: FACT-O
Description: Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
Study: NCT01845675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide or dacarbazine-based chemotherapy, endostatin
Study: NCT01467180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: septeX
Description: continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF CVVH
Description: continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h